The company "has received the approval for the generic version of 'Sofosbuvir+Velpatasvir' combination from the Drugs Controller General of India (DCGI)", Hetero said in a statement.
The product will be marketed and distributed under the brand name 'Velasof' in India by Hetero Healthcare Ltd, it added.
"This fixed-dose combination is the generic version of Gilead's brand Epclusa, approved by the USFDA for the treatment of patients with chronic hepatitis C genotype 1 to 6," Hetero said.
Disclaimer: No Business Standard Journalist was involved in creation of this content